BioVersys AG, a clinical-stage biopharmaceutical company developing novel antibacterial products, announced that it will present new data on alpibectir in combination with ethionamide (AlpE) at The Union World Conference on Lung Health, taking place from 17 to 20 November 2026 in Rio de Janeiro, Brazil. The presentations, conducted with development partner GSK, will include the latest Phase 2 results in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. The conference brings together global experts to accelerate progress in lung health, and the alpibectir data could significantly impact tuberculosis treatment by offering a new regimen that lowers the required dose of ethionamide, reduces side effects, and overcomes resistance.
The schedule features multiple presentations, including an e-poster on early bactericidal activity, safety, and pharmacokinetics by Dr. Simphiwe RN Simelane on 18 November; a session on alpibectir potentiating ethionamide activity by Dr. Michel Pieren on 19 November; and a presentation on ENABLE trial results by Dr. Simelane later that day. Dr. Simon Tiberi will present on further development of alpibectir-containing regimens on 20 November. These findings are highly anticipated as they may validate a novel approach to tuberculosis therapy, which remains a major global health challenge. The data could support regulatory submissions and eventual market approval, especially given that AlpE received orphan-drug designation from the U.S. FDA in 2023 and Orphan Designation from the European Medicines Agency in 2025, providing incentives such as market exclusivity.
Alpibectir, developed from BioVersys’ TRIC platform in collaboration with GSK, the Institut Pasteur Lille, and the University of Lille, acts through a novel mode of action to potentiate ethionamide. This could lead to a shorter, more tolerable treatment regimen, addressing the high unmet need for new tuberculosis treatments. The Phase 2 data being presented at the conference will provide critical insights into the combination’s efficacy and safety, potentially paving the way for late-stage development. For BioVersys, a successful outcome would strengthen its pipeline and partnership with GSK, while also contributing to global efforts to combat drug-resistant tuberculosis. The presentations at the Union Conference underscore the importance of collaborative research in advancing new therapies for lung health.
For more information, visit www.bioversys.com or view the original release on www.newmediawire.com.


